CCR7 and COVID-19: In addition, the proportion of some effector phenotype subpopulations showed an augmentation in COVID-19 patients compared to healthy controls, including the effector memory (EM, CCR7-/CD45RA-) phenotype in both CD4+: 25.8% (18.6–35.2) vs. 18.3% (13.6–24.9)(p = 0.001) and CD8+ T-cells: 48.1% (40–60.2) vs. 42% (26.6–49.9) (p < 0.001, Table 2) and terminal differentiated effector memory re-expressing CD45RA (TEMRA, CCR7-/CD45RA+) CD8+ cells: 20.5% (11–30.5) vs. 10% (7.5–24.5) (p = 0.003, Table 2).